{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2629292"],"location":["Japan"],"study_start_month":["1"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"TS-1+ Oxaliplatin+ Bevacizumab therapy in consideration of OPTIMOX design for metastatic colorectal cancer","description":"Interventions: TS-1+ Oxaliplatin+ Bevacizumab/TS-1+ Bevacizumab\nPrimary outcome(s): DDC ; Duration of disease control\nStudy Design: Single arm Non-randomized","dates":{"creation":"2013-01-15"},"accession":"2629292","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000013945"]}}